Sarepta Therapeutics Inc - Asset Resilience Ratio
Sarepta Therapeutics Inc (SRPT) has an Asset Resilience Ratio of 6.82% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SRPT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2025)
This chart shows how Sarepta Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Sarepta Therapeutics Inc (SRPT) total assets.
Liquid Assets Composition Over Time
This chart breaks down Sarepta Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Sarepta Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $217.34 Million | 6.82% |
| Total Liquid Assets | $217.34 Million | 6.82% |
Asset Resilience Insights
- Limited Liquidity: Sarepta Therapeutics Inc maintains only 6.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sarepta Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sarepta Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
ChemPartner PharmaTech Co Ltd
SHE:300149 |
Biotechnology | 1.67% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 59.25% |
Annual Asset Resilience Ratio for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual Asset Resilience Ratio data for Sarepta Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.13% | $138.37 Million | $3.35 Billion | -2.22pp |
| 2024-12-31 | 6.35% | $251.78 Million | $3.96 Billion | -31.87pp |
| 2023-12-31 | 38.22% | $1.25 Billion | $3.26 Billion | +5.54pp |
| 2022-12-31 | 32.69% | $1.02 Billion | $3.13 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $3.15 Billion | -- |
| 2020-12-31 | 14.61% | $435.92 Million | $2.98 Billion | -1.29pp |
| 2019-12-31 | 15.89% | $289.67 Million | $1.82 Billion | -33.02pp |
| 2018-12-31 | 48.91% | $803.08 Million | $1.64 Billion | +12.26pp |
| 2017-12-31 | 36.65% | $479.37 Million | $1.31 Billion | -9.43pp |
| 2016-12-31 | 46.08% | $195.43 Million | $424.10 Million | +5.10pp |
| 2015-12-31 | 40.98% | $112.19 Million | $273.78 Million | -5.39pp |
| 2014-12-31 | 46.37% | $136.79 Million | $295.03 Million | +43.88pp |
| 2013-12-31 | 2.49% | $7.25 Million | $291.57 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $204.99 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $54.37 Million | -- |
| 2009-12-31 | 0.28% | $171.00K | $60.03 Million | -0.82pp |
| 2008-12-31 | 1.10% | $282.06K | $25.54 Million | +0.40pp |
| 2007-12-31 | 0.70% | $271.85K | $38.64 Million | -31.09pp |
| 2006-12-31 | 31.80% | $12.99 Million | $40.86 Million | +9.72pp |
| 2005-12-31 | 22.08% | $12.45 Million | $56.41 Million | +12.05pp |
| 2004-12-31 | 10.03% | $2.86 Million | $28.52 Million | -43.16pp |
| 2003-12-31 | 53.19% | $25.07 Million | $47.15 Million | +22.04pp |
| 2002-12-31 | 31.15% | $8.91 Million | $28.60 Million | -11.82pp |
| 2001-12-31 | 42.96% | $14.53 Million | $33.82 Million | +25.25pp |
| 2000-12-31 | 17.71% | $6.21 Million | $35.09 Million | -4.77pp |
| 1999-12-31 | 22.48% | $2.90 Million | $12.90 Million | +13.78pp |
| 1995-12-31 | 8.70% | $200.00K | $2.30 Million | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more